Sutro Biopharma Inc Dossier - Source-backed chat

Sutro Biopharma Inc

STRONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.34

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $15.97Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $264.8M

Shares Outstanding 14.9M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Sutro Biopharma is a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug conjugates (ADCs) using its proprietary cell-free protein synthesis platform, XpressCF. The company is transitioning into a high-catalyst period with its lead wholly-owned asset, STRO-004 (a Tissue Factor-targeting ADC), poised to report initial Phase 1 clinical data in mid-2026. Backed by a robust cash runway extending into at least Q2 2028 following a successful $110 million capital raise, and validated by high-value pharmaceutical partnerships (such as Astellas), Sutro represents a compelling investment opportunity in the rapidly expanding ADC space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$47.75

High · most bullish analyst$61.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$10.0020%

STRO-004 Phase 1 data reveals unexpected toxicities or insufficient clinical efficacy, undermining the competitive positioning of the asset and casting doubt on the platform's clinical translation. Delays in IND filings for STRO-006 or STRO-227, combined with a lack of near-term milestone payments, accelerate cash burn and force dilutive financing measures under unfavorable market conditions.

Base CaseCentral scenario

$47.7550%

Matches the consensus mean

STRO-004 Phase 1 data shows a favorable safety profile and encouraging early antitumor activity, validating the cell-free platform's ability to optimize drug exposure. IND submissions for STRO-006 and STRO-227 proceed on track in 2026. The company maintains disciplined financial stewardship, preserving its cash runway into 2028, while steady progress in partnered programs supports a gradual re-rating toward consensus analyst targets.

Bull CaseUpside scenario

$60.0030%

STRO-004 Phase 1 clinical data in mid-2026 demonstrates superior safety (specifically reduced bleeding risk) and robust efficacy compared to benchmark Tissue Factor ADCs, establishing it as a potential best-in-class therapeutic. Rapid clinical entry of STRO-006 and STRO-227 in late 2026 accelerates the pipeline, while the Astellas-partnered dual-payload iADC triggers additional high-margin milestone payments, driving significant upward valuation adjustments.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary cell-free protein synthesis platform (XpressCF) enabling precise, site-specific conjugation of single- and dual-payload ADCs.
Strong balance sheet with $202.6 million in cash and marketable securities as of March 31, 2026, extending the operational runway into at least Q2 2028.
Imminent clinical catalyst with initial Phase 1 data for lead asset STRO-004 expected in mid-2026.
Validation and non-dilutive funding from established pharmaceutical collaborations, including a $10 million milestone achieved under the Astellas partnership in April 2026.

Key Investment Risks

High clinical-stage development risk, with the upcoming STRO-004 Phase 1 readout representing a binary valuation event.
Regulatory hurdles and potential delays in obtaining IND clearances for preclinical candidates STRO-006 and STRO-227.
Intense competition within the oncology and ADC landscapes from both established pharmaceutical giants and emerging biotech players.
Long-term reliance on capital markets or partnership milestones to fund operations prior to commercial product sales.

Thesis Invalidation Triggers

Failure of STRO-004 to demonstrate acceptable safety, tolerability, or early efficacy in the Phase 1 dose-escalation trial.
Inability to submit INDs for STRO-006 and STRO-227 within the projected 2026 timeline.
Termination or material negative restructuring of key pharmaceutical collaborations, such as the Astellas partnership.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.